Understanding the RECORDS 3 Trial and its impact on anticiagulation practice in resource poor countries

Abstract

Venous thromboembolism is a significant cause of mortality and morbidity in patients following major orthopaedic surgeries. The RECORDS 3 trial revolutionised anticoagulation practice especially in patients with total knee arthroplasty and challenging the strong hold of warfarin and heparin in anticoagulation practice. With all these novel agents shifting the paradigm in anticoagulation management, Cost, in accessibility and lack of awareness of the availability of the agents amongst clinicians and surgeons alike are some factors militating against the use of these agents in patients in resource poor countries.

Keywords: Anticoagulation practice, new anticoagulation therapy, Regulation of Coagulation in Orthopedic surgery to prevent Deep venous thrombosis and pulmonary embolism 3 trial, rivaroxaban